The effect of tobacco on lung cancer risk depends on CYP2D6 activity

Cancer Research

Volumn 56, Issue 2, 1996, Pages 251-253

  Bouchardy, Christine ^a   Benhamou, Simone ^b   Dayer, Pierre ^c  

^a GENEVA CANCER REGISTRY   (Switzerland)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DEXTROMETHORPHAN;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; GENETIC SUSCEPTIBILITY; HUMAN; LUNG CARCINOGENESIS; LUNG CARCINOMA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SMOKING;

AGE FACTORS; AGED; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; FRANCE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; RISK FACTORS; SMOKING;

EID: 0030047286     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Gonzalez, F. J., and Idle, J. R. Pharmacogenetic phenotyping and genotyping: present status and future potential. Clin. Pharmacokinet., 26: 59-70, 1994.
2. Crespi C. L., Penman, B. W., Gelboin, H. V., and Gonzalez, F. J A tobacco smoked-derived nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic human cytochrome P4502D6. Carcinogenesis (Lond.), 12: 1197-1201, 1991.
3. Caporaso, N., DeBaun, M. R., and Rothman, N. Lung cancer and CYP2D6 (the débrisoquine polymorphism) sources of heterogeneity in proposed association Pharmacogenetics, 5: 129-134, 1995
4. IARC. Tobacco smoking Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, IARC Scientific Publications, Vol. 38, pp 221-228. Lyon, France: International Agency for Research on Cancer, 1986.
5. Dayer, P , Leeman, T., and Striberni, R. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 dbl activity. Clin Pharmacol. & Ther., 45 34-40, 1989
6. Breslow, N E., and Day, N. E The analysis of case-control studies. In: Statistical Methods in Cancer Research, IARC Scientific Publications, Vol. 1, No. 32, pp. 192-242. Lyon, France: International Agency for Research on Cancer, 1980.
7. Baker, R. J , and Nelder, J A Generalized linear interactive modelling (GLIM) system, release 3. Oxford: Numerical Algorithms Group, 1978.
8. Cholerton, S., Arpanahi, A., McCracken, N., Boustead, C., Taber, H., Johnstone, E., Leathart, J , Daly, A. K., and Idle, J. R. Poor metabolisers of nicotine and CYP2D6 polymorphism Lancet, 343: 62-63, 1994.
9. Nakachi, K., Imai, K , Hayashi, S., and Kawajiri, K. Polymorphisms of the CYP1A1 and glutathione S-transferase genes associated with susceptibility to lung cancer in relation to cigarette dose in Japanese population Cancer Res , 53: 2994-2999, 1993.
10. Uematsu, F., Ikawa, S , Kikuchi, H , Sagami, I., Kanamaru, R., Abe, T., Satoh, K., Motomiya, M., and Watanabe, M. Restriction fragment length polymorphism of the human CYP2E1 (cytochrome P450IIE1) gene and susceptibility to lung cancer: possible relevance to low smoking exposure. Pharmacogenetics, 4: 58-63, 1994.
11. Kihara, M., Kihara, M., and Noda, K. Lung cancer risk of GSTM1 null genotype is dependent on the extent of tobacco smoke exposure. Carcinogenesis (Lond ), 15: 415-418, 1994.
12. Steiner, E., Iselius, L., Alvan, G , Lindsten, J., and Sjoqvist, F. A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin. Pharmacol. & Ther., 38. 394-401, 1985.
13. Ayesh, R , Idle, J R., Ritchie, J C., Crothers, M. J , and Hetzel, M R Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature (Lond.), 312. 169-170, 1984.
14. Law, M R., Hetzel, M R., and Idle, J. R. Debrisoquine metabolism and genetic predisposition to lung cancer. Br. J Cancer, 59: 686-687, 1989
15. Caporaso, N , Tucker, M. A., Hoover, R. N., Hayes, R. B., Pickle, L. W., Issaq, H J., Muschik, G M , Green-Gallo, L., Buivys, D , Aisner, S., Resau, J. H., Trump, B. F , Tollerud, D , Weston, A., and Harris, C. C. Lung cancer and the debrisoquine metabolic phenotype. J. Natl. Cancer Inst. 82: 1264-1271, 1990.
16. Roots, I , Drakoulis, N., Ploch, M., Heinemeyer, G., Loddenkemper, R , Minks, T . Nitz, M., Otte, F., and Koch, M Debrisoquine hydroxylation phenotype, acetylation phenotype, and ABO blood groups as genetic host factors of lung cancer risk. Klin. Wochenschr., 66 87-97, 1988
17. Pillière, F , Dalphin, J C., De Palmas, J., Duche, J. C., and Brochard, P. Recherche d'une prédisposition génétique au cancer bronchopulmonaire primitif par l'étude du phénotype d'hydroxylation de la débrisoquine Arch. Mal. Prof Med. Trav. Secur. Soc., 51: 11-16, 1990.
18. Duche, J. C., Joanne, C , Barre, J., de Cremoux, H., Dalphin, J. C., Depierre, A , Brochard, P., Tillement, J P., and Bechtel, P. Lack of relationship between the polymorphism of debrisoquine oxidation and lune cancer. Br. J. Clin. Pharmacol , 31: 533-536, 1991.